Shandong Wohua Pharmaceutical Co (002107) Fair Value & Analysis

Healthcare · CN · Market cap 3.5B CNY

A strong business, but screening 42% overvalued on our models.

What matters now

• A high-quality business (quality 86/100), yet the market already pays well above fair value. Quality at a full price, with little margin of safety.
• The price sits above even our optimistic bull case (¥4.49). The favourable scenario is already priced in.

Price vs Fair Value (5 years)

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 22, 2026.

How to read this chart

60‑month range ¥3.23 – ¥8.11 · fair‑value band ¥2.74 – ¥4.49 · the ¥6.30 price screens above the ¥3.65 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 22, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Shandong Wohua Pharmaceutical Co (002107) currently trades at ¥6.30, while our model-based Fair Value estimate is ¥3.65, implying the stock looks roughly 42.1% overvalued today. The Quality Score stands at 86/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).

Over the trailing twelve months, Shandong Wohua Pharmaceutical Co generated revenue of 818M CNY at a net margin of 13.4%. Revenue grew 0.6% year over year. It earns a return on equity of 14.9%. The balance sheet holds a net cash position of 392M CNY. Fundamentals as of Jul 22, 2026

Our scenario range runs from ¥2.74 (bear case) to ¥4.49 (bull case); at ¥6.30, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 26% below its 52-week high and 20% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -49% fair-value upside, at -42%, 002107 screens cheaper than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Widest divergence: DCF Models (¥4.47) versus Asset-Based (¥0.8400). Highest evidence: Growth DCF (80).

Key figures & financial health

Quality Score breakdown

About the company

Shandong Wohua Pharmaceutical Co., Ltd. manufactures and sells pharmaceutical products in China. The company produces and sells tablets, granules, capsules, oral liquid, and pills; medicinal herb cultivation; and provides pharmaceutical technology consulting services.

Full company description

Shandong Wohua Pharmaceutical Co., Ltd. manufactures and sells pharmaceutical products in China. The company produces and sells tablets, granules, capsules, oral liquid, and pills; medicinal herb cultivation; and provides pharmaceutical technology consulting services. It also offers products including drugs for cardiovascular, cerebrovascular, and nervous system diseases, such as Wohua Xinkeshu tablets, Hedan tablets and capsules, Naoxueshu and Shenzhiling oral liquid, and Tongluo Huatan capsules; and drugs for musculoskeletal disorders, including Gusukang capsules/granules and Yidu Hanbi liquid; Yidu cold-rheumatism medicinal wine ingredients; brain blood circulation oral solution; Amber stone granules for urinary system diseases; Children's antipyretic granules for pediatric medication; Anti-itching granules for skin diseases; and Bile grass capsule for digestive and gynecological diseases, as well as Silkworm Nourishing Blood and Benefiting Kidney Granules for gynecological medication. In addition, the company offers Amber Xiaoshi granules, and Siyu Yangxue Yishen granules; Yanreqing granules, Antiviral oral liquid, and Niuhuang Yijin tablets for the treatment of dry throat and sore throat; Yinhuang granules for the treatment of wind-heat colds; Tongxuan Lifei pills for the treatment of wind-cold colds; Fangfeng Tongsheng pills for colds on the surface and heat inside; Huoxiang Zhengqi Water for the treatment of summer-heat colds; Shenling Baizhu, Buzhong Yiqi, and Xiangsha Liujun pills for the treatment of physical weakness colds; and Juhong Li Gao for the treatment of dry coughs with little sputum. The company was founded in 2003 and is based in Weifang, China. Shandong Wohua Pharmaceutical Co., Ltd. operates as a subsidiary of Beijing Zhongzheng Wanrong Investment(Group) Co., Ltd.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Shandong Wohua Pharmaceutical Co reported revenue of ¥817M in FY2025 versus ¥943M in FY2021, a compound −3.5%/yr. Reported net income was ¥95.7M in FY2025, compounding −12.5%/yr from FY2021.

002107 screens 42% overvalued. Compare with Jiangsu Hengrui Pharmaceuticals Co →

Peer Group

Drug Manufacturers - Specialty & Generic · 626 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Valuation Multiples vs Drug Manufacturers - Specialty & Generic median · lower = cheaper

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 0: the price sits above our fair-value range.

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 22, 2026).

Explore undervalued stocks

More undervalued Healthcare stocks →

Frequently asked questions

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.